NASDAQ:OBLNObalon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Obalon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.70 -0.01 (-1.40 %) (As of 07/6/2020 04:00 PM ET) Add Compare Share Today's Range$0.70Now: $0.70▼$0.7450-Day Range$0.69MA: $0.88▼$1.1952-Week Range$0.62Now: $0.70▼$10.50Volume67,700 shsAverage Volume443,453 shsMarket Capitalization$5.43 millionP/E RatioN/ADividend YieldN/ABeta-1.12 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingObalon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Obalon Therapeutics has a potential upside of 1,324.5% from its current price of $0.70.Amount of Analyst CoverageObalon Therapeutics has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesObalon Therapeutics has received 245 “outperform” votes. (Add your “outperform” vote.)Underperform VotesObalon Therapeutics has received 265 “underperform” votes. (Add your “underperform” vote.)Community SentimentObalon Therapeutics has received 51.96% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote “Outperform” if you believe OBLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldObalon Therapeutics does not currently pay a dividend.Dividend GrowthObalon Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Obalon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.30% of the stock of Obalon Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 13.55% of the stock of Obalon Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Obalon Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Obalon Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioObalon Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBLN Previous Symbol CUSIPN/A CIK1427570 Webwww.obalon.com Phone844-362-2566Debt Debt-to-Equity Ratio0.09 Current Ratio2.17 Quick Ratio1.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.28 million Price / Sales1.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book0.34Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-23,680,000.00 Net Margins-903.19% Return on Equity-149.15% Return on Assets-98.93%Miscellaneous Employees100 Outstanding Shares7,732,000Market Cap$5.43 million Next Earnings Date7/22/2020 (Estimated) OptionableOptionable NASDAQ:OBLN Rates by TradingView Receive OBLN News and Ratings via Email Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions How has Obalon Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OBLN stock has decreased by 32.5% and is now trading at $0.7020. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Obalon Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Obalon Therapeutics. When is Obalon Therapeutics' next earnings date? Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Obalon Therapeutics. How were Obalon Therapeutics' earnings last quarter? Obalon Therapeutics Inc (NASDAQ:OBLN) announced its quarterly earnings results on Friday, June, 19th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.17. The firm earned $0.78 million during the quarter. Obalon Therapeutics had a negative return on equity of 149.15% and a negative net margin of 903.19%. View Obalon Therapeutics' earnings history. When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work? Obalon Therapeutics's stock reverse split on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for OBLN? 2 brokers have issued 12 month price targets for Obalon Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Obalon Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 1,324.5% from the stock's current price. View analysts' price targets for Obalon Therapeutics. Has Obalon Therapeutics been receiving favorable news coverage? Media headlines about OBLN stock have trended negative on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obalon Therapeutics earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Obalon Therapeutics. Who are some of Obalon Therapeutics' key competitors? Some companies that are related to Obalon Therapeutics include Biostage (BSTG), Sintx Technologies (SINT), Endologix (ELGX), Dynatronics (DYNT), Lianluo Smart (LLIT), Avinger (AVGR), Hancock Jaffe Laboratories (HJLI), PlusTherapeuticsInc . (PSTV), Hypertension Diagnostics (HDII), Encision (ECIA), CELLECT BIOTECH/S (APOP), Invivo Therapeutics (NVIV), RA Medical Systems (RMED), Cytocore (MDIT) and Neurometrix (NURO). View all competitors. What other stocks do shareholders of Obalon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Opko Health (OPK), Inpixon (INPX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Zynerba Pharmaceuticals (ZYNE), Co-Diagnostics (CODX) and Corbus Pharmaceuticals (CRBP). Who are Obalon Therapeutics' key executives? Obalon Therapeutics' management team includes the following people: Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)Mr. William John Plovanic CFA, CFO & Sec. (Age 50)Mr. Mark C. Brister, Chief Technology Officer (Age 57)Ms. Daina Schmidt, VP of Marketing When did Obalon Therapeutics IPO? (OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager. What is Obalon Therapeutics' stock symbol? Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN." How do I buy shares of Obalon Therapeutics? Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Obalon Therapeutics' stock price today? One share of OBLN stock can currently be purchased for approximately $0.70. How big of a company is Obalon Therapeutics? Obalon Therapeutics has a market capitalization of $5.43 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe. What is Obalon Therapeutics' official website? The official website for Obalon Therapeutics is www.obalon.com. How can I contact Obalon Therapeutics? Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
